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PATHOGENESIS OF INTRACRANIAL ANEURYSMS 
BRIAN V. NAHED  AND  MURAT GUNEL 
Department of Neurosurgery, Yale University School of Medicine, New Haven, CT. 
 
Introduction: 
Intracranial aneurysms (IA) are a common neurological problem, the rupture of which 
frequently constitutes a catastrophic neurological event. While the pathogenesis is largely 
unknown, it is believed that both genetic and environmental factors work in concert to 
some degree within patients. Our goal was to take a comprehensive approach to 
understanding the pathogenesis of IA by identifying factors leading to the formation, 
growth and rupture of IA.  
 
Methods: 
Since 1994, we have recruited patients and families with IA into the Yale Brain 
Aneurysm Database.  Information regarding aneurysm characteristics (size, location, 
number), patient characteristics (age, medical, and social history), and family history 
were recorded. We analyzed this database for environmental factors associated with 
aneurysmal rupture. Within the same database, we identified and analyzed kindreds with 
a high IA incidence and penetrance using genome-wide linkage analysis. Collaborations 
with other centers provided additional kindreds to analyze and confirm our results. 
 
Results: 
Analysis of our database revealed hypertensive patients with IA ≤ 7mm were 2.6 times 
more likely to rupture (p = .01, 95% CI: 1.21, 5.53) than normotensive patients. Posterior 
circulation aneurysms were 3.5 times more likely to rupture than anterior circulation 
aneurysms (p = .048, 95% CI: 0.95, 19.4). Further, genome-wide linkage analysis 
revealed significant linkage to a single locus, with a lod score of 4.2 at 1p34-36. 
 
Conclusions: 
We identified hypertension, young age, and posterior circulation as significant risk 
factors for rupture among patients with small aneurysms (≤ 7mm). Additionally, we are 
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Aneurysmal subarachnoid hemorrhage (SAH) is a serious neurosurgical 
emergency with poor prognosis; approximately 12% of patients die before reaching 
medical attention (1), and 40% die in hospital care (2-4).  Survivors of SAH frequently 
leave the hospital severely disabled requiring a lifetime of care (5, 6). 
Although the majority of intracranial aneurysms (IA) do not rupture, those that do 
account for around 85% of SAH (7).  The incidence of SAH is 6 in 100,000 per year with 
approximately 28,000 ruptures per year. Those individuals who survive the initial bleed 
experience a 40% mortality rate during the first month; 25% of those who live past the 
first month recover completely (8).  
SAH accounts for 3% of all strokes (8), 5% of stroke deaths, and more than one-
quarter of potential life years are lost through stroke (9). Although the 20th century has 
seen great advances in diagnosis, treatment, and prevention of complications of SAH, the 
overall outcome has only modestly improved (10) leaving formidable challenges ahead 
for physicians caring for these patients. 
Given the devastating sequelae of SAH, surgical or endovascular intervention 
prior to rupture is considered to be of paramount importance. Guidelines have been 
established to assist in the decision between treatment and careful monitoring, with the 
goal of prophylactically treating those aneurysms that are likely to rupture. Attempts to 
identify risk factors and the pathophysiology leading to aneurysm formation and rupture 
have been unsuccessful. 
By studying populations in which the etiology of IA is relatively homogeneous 






Intracranial aneurysms (IA) are characterized by abnormal localized dilatations 
representing cerebral arterial wall compromise. The origin of the word aneurysm stems 
from the Latin word aneurysma, which means dilatation. IA affect 5 – 10 % of the 
general population (11) and represent a major public health problem. It is estimated that 
2.3% of the population have undetected aneurysms (12), the majority of which will not 
rupture. When they rupture, the morbidity and mortality is devastating with 
approximately half resulting in immediate death.  
Currently there are no reliable screening methods to identify at-risk individuals. 
Therefore, clinicians resort to imaging at-risk individuals (loosely defined as having a 
parent or sibling with IA) using magnetic resonance angiography (MRA) or 
computerized tomography angiography (CTA). Moreover, there are no widely accepted 
guidelines defining high-risk individuals.  
For many years, the decision to operate on an unruptured aneurysm was based 
solely on the size of the aneurysm determined by imaging studies.  One large multi-center 
trial suggested that IA ≥ 10 mm had a risk of rupture of 1% per year (13) with smaller 
aneurysms having a much smaller risk of rupture. However, this initial data conflicted 
with clinical experience in which a significant number of patients present with SAH due 
to aneurysms less than 10 mm in size.  Furthermore, the data contradicted a previously 
published series in which aneurysms <10 mm were at risk of rupture (14). 
Progress in understanding the pathogenesis of IA has been hampered by its multi-
factorial nature. Neither the conditions that lead to aneurysm formation nor rupture are 
well understood. Instead, clinicians are left to speculate on the importance of risk factors 




history when deciding the degree of intervention. Given the large number of familial 
cases and increased incidence with other genetic diseases such as adult polycystic kidney 
disease (ADPKD), the genetic basis of aneurysms has been alluded to but a gene has yet 
to be identified.  
Recent studies suggest that both environmental and genetic factors contribute to 
the pathogenesis of IA. The degree to which each contributes to an individual’s aneurysm 
is likely patient specific. We aim to identify both the genetic mutations and 
environmental factors that work independently and synergistically to form IA. 
 
ENVIRONMENT 
 The literature is rich with association studies linking risk factors with the 
formation and rupture of aneurysms. Guidelines have been established to identify which 
aneurysms should be treated and which need to be watched. Until now, these guidelines 
have been largely based around aneurysm size and location.  
 
Aneurysm Size 
The notion that aneurysm size correlates with rupture risk is as old as aneurysm 
surgery itself. Blood vessel walls are exposed to a combination of hydrostatic pressure 
and shearing stress. It is thought that aneurysm wall stress and eventual rupture is directly 
correlated with aneurysm size. Prior to the 1990s, aneurysms greater than 10 mm were 
considered at high risk for rupture and treated surgically. However, contrary to the 
guidelines, aneurysms < 10 mm did rupture and led to SAH in significant numbers, 




Recent studies, including the prospective arm of the International Study of 
Unruptured Intracranial Aneurysms (ISUIA), suggest aneurysms < 10 mm in size have 
higher than previously predicted rates of rupture (15).  These studies led to the 
adjustment of clinical guidelines that treatment with either microsurgical or endovascular 
techniques should be considered with aneurysms > 7mm in size (15).  Despite this 
recommendation a significant number of patients present with SAH due to aneurysms ≤ 7 
mm in daily clinical practice.  In addition, several studies have shown the decision to 
treat unruptured aneurysms should not be based on aneurysm size alone (16-20).  
However, the results of these studies are not yet incorporated into the treatment 
guidelines. 
 
Other Risk Factors 
Many studies have attempted to identify risk factors, other than size, that predict 
the formation, growth, and rupture of IA. Factors such as hypertension, atherosclerosis, 
diabetes, and vascular anatomical differences have been implicated in pathogenesis (4, 
21). In addition, social factors such as smoking and diet have also been suggested to play 
a role in the disease (4, 22). Although family history and the above-mentioned modifiable 
risk factors have been suggested to increase the risk of rupture, there is insufficient data 
to support a definitive clinical recommendation for surgical treatment of small 
aneurysms. (23-33)  
A review by Teunissen et al. revealed only hypertension, cigarette smoking, and 
alcohol consumption (greater than 150 g / week) were significant risk factors (34). These 
results were confirmed in a review of five trials (North America, Canada, and Europe) 




While there is evidence for environmental factors contributing to the pathogenesis 
of IAs, they fail to explain the complete picture, especially in young adults. Thus, genetic 
factors, particularly in the younger population, have been suggested to play a crucial role 
in the pathogenesis of aneurysm formation. 
 
GENETICS 
It is now well accepted that genetic risk factors, in addition to environmental risk 
factors, contribute to the formation and / or rupture of cerebral aneurysms. In this section, 
we highlight familial intracranial aneurysms and previous linkage analysis studies. 
 
Familial Aneurysms 
The notion that aneurysms cluster in families was first noticed in identical twins 
during the 1960s. Ullrich and Sugar reported 4 families, each with at least 2 members 
with cerebral aneurysms (35).  This was followed by several case reports of multiple 
familial IA (36-41). 
In 1980, Fox and Ko reported the largest family reported to date of thirteen 
siblings, 6 had proven IA and 5 had normal findings on cerebral angiogram; 2 refused 
angiogram (42). Subsequently, one of the two who refused workup suffered a SAH and 
was found to have 2 aneurysms by angiogram. Interestingly, there was no disease in their 
parents and relatives. Since then, we have ascertained and recruited this family in our 
study (IA 20, figure 3) and found that there are newly affected members in subsequent 
generations. 
In 1993, Ronkainen et al reported a 10% incidence of familial IAs in family 




Similarly, Kojima et al. reported a 10% prevalence of IAs in families with positive 
history (43).  Two studies, a prospective and retrospective study, found a three to five 
fold increase in incidence for first degree relatives in comparison to the general 
population (44). 
A study spanning from 1970 to 1989 evaluated the families of patients with 
aneurysmal SAH reporting that 15 of 76 patients (20%) had a first- or second-degree 
relative with aneurysmal SAH (45).  The number of observed first-degree relatives with 
aneurysmal SAH was 11, compared to an expected number of 2.66, giving a relative risk 
of 4.14.  
Nakagawa et al. found a significantly higher incidence of asymptomatic cerebral 
aneurysms among Japanese patients with family history of SAH within the second degree 
of consanguinity versus healthy volunteers (13.9% versus 6%) (46). When combined 
with other risk factors such as hypertension and habitual smoking, these patients were 
found to have the highest incidence. 
Several studies have reported that familial IA behave differently than sporadic IA.  
Familial cases are detected at an earlier age and ruptured at a smaller size when compared 
to sporadic cases (47-51). In fact, 70% of familial IA rupture by the age of 50 versus 43% 
of non-familial aneurysms (47).  Additionally, a study by Leblanc et al. found higher than 
expected concordance of the age at rupture in a prospective study of 30 individuals in 13 
families with multiple affected individuals (52). In the Saguenay-Lac Saint Jean region of 
the Province of Quebec, Canada, Mathieu et al. found that siblings of patients with 
ruptured IA had a greater risk of ruptured IA than the general population (53).  
IA transmission from generation to generation has been difficult to determine. A 




one pattern of inheritance nor Mendelian model that uniformly applied (44). The most 
commonly affected relatives were siblings.  Twenty-two percent of siblings of male 
probands had an IA compared with 9% of sibs of female probands. Interestingly, 
angiographic screening in 12 families detected IAs in 29% of 51 asymptomatic relatives. 
Although genetic heterogeneity might be present, screening of asymptomatic relatives 
could provide information as to the mode of inheritance. There is significant debate over 




While several candidate genes have been implicated in the pathogenesis of 
aneurysms, none have led to any significant findings.  These genes range from those 
associated with vascular wall formation to those that are mutated in connective tissue 
disorders. By studying known genetic diseases with high concordance of IA, researchers 
have identified proteins associated with the genetic disease as potentially related to the 
pathogenesis of aneurysms. Diseases such as Adult Polycystic Kidney Disease (MIM 
#173900) (54), Marfan syndrome (MIM #154700) (55), Glucocorticoid Remediable 
Aldosteronism (MIM #103900) (56), and Ehlers-Danlos syndrome type IV (MIM 
#130050) (57), appear to increase the risk of IA formation. This phenomenon prompted 
researchers to study the gene and gene products responsible for the disease with the hopes 
of explaining the increased IA formation. 
Recent advances in genetic disorders and vascular abnormalities have revealed 
several alterations in gene and gene products involved in the remodeling of the 




awry leading to a weakening of the vasculature ultimately resulting in an aneurysm. 
Supporting this notion, the content and structure of collagen and elastin, the predominant 
elements in aneurysmal walls, is significantly altered. The below mentioned ECM-related 
proteins have been identified in genetic disorders and could be related to IA formation. 
 
Elastin 
In 2001, a genome-wide linkage study of 104 Japanese affected sib-pairs 
identified an area near the elastin gene (ELN) as the best evidence of linkage (58). 
Linkage was found at a total of three sites: 5q22-q31 (maximum lod score (MLS), 2.24), 
7q11 (MLS, 3.22), and 14q22 (MLS, 2.31). None of the fourteen SNPs identified within 
ELN were associated with aneurysms. However, the haplotype between intron-20 / 
intron-23 polymorphism of ELN was strongly associated with intracranial aneurysms [P 
= 3.81 x 10(-6)]. Further, patients who were homozygous for the mutation were at highest 
risk (P = 0.002), with an odds ratio of 4.39. These findings strongly support the body of 
literature implicating the ELN locus in aneurysm genesis, more specifically the locus on 
chromosome 7q11.2.  However, no frank mutation was identified. 
 
Elastase / α1-Antitrypsin  
Elastase is a proteolytic enzyme that degrades elastin, collagen, and other proteins 
within the ECM (59-61). Secreted by polymorphonuclear leukocytes, it is inactivated 
once it binds to α1-antitrypsin forming a serum complex with protease (62, 63). The 
balance between active and inactive elastase has been implicated in aneurysmal 
formation. Tartara et al have suggested that α1-antitrypsin activity is decreased in the 




the site of intracranial aneurysms. (65) Although controversial, these complimentary 
studies suggest that α1-antitrypsin levels are decreased at the site of aneurysms leading to 
increases in elastase levels. However, two studies contradict these findings demonstrating 
elevated elastase levels in healthy individuals without aneurysms. (66, 67) Debate over 
the importance of this ratio will require further work delineating aneurysmal causes from 
those of normal physiology.  
 
Collagen (I and III) 
Studies have uniformly demonstrated a decrease and alteration in the collagen 
within aneurysmal walls. In particular, a deficiency in type III collagen occurs within 
aneurysm walls. (68-73). Studies have proposed a defect in type III collagen (COL3A1) 
(57, 72). EDS type IV is a connective tissue disorder caused by mutations in the COL3A1 
gene on chromosome 2q31. EDS type IV is characterized by vascular abnormalities 
consisting of increased ruptures, thin transparent skin, and ligament weakness. 
Ostergaard and Oxlund demonstrated 6 of the 14 patients who died from ruptured 
intracranial aneurysms had type III collagen deficiency in the middle cerebral and 
brachial artery postmortem. (71) However, others have suggested that mutations in the 
COL3A1 gene are not a common cause of intracranial aneurysms nor are cervical artery 
dissections. (74) Although collagen constitutes the majority of the ECM, its role in 
aneurysm formation, and it’s ratio to collagen III, remains unclear.  
 
Endoglin 
Endoglin, a component of the transforming growth factor-beta receptor complex 




between intracranial aneurysms and a 6-base insertion polymorphism in intron 7 of the 
endoglin gene in a Japanese population. (75) This region codes for a component of the 
transforming growth factor-ß receptor complex and is also mutated in Hereditary 
Hemorrhagic Telengiectasia 1 (HHT1).  However, two other studies, one on a Caucasian 
population (63) and another on a separate Japanese population (58) failed to replicate this 
result. 
The discrepancy in results from the above-mentioned studies suggests that 
polymorphism sequences are likely influenced by genetic and environmental factors 
which differ according to ethnicity. To prove this point, ethnic related differences are 
reported for polymorphisms and are considered within the norm. While the Krex and 
Onda studies refute the findings of Takenaka’s study, it is possible that endoglin encodes 
multiple proteins, one of which could lead to aneurysm formation. The polymorphisms 
expressed in endoglin represent one of the many reasons genetic testing is complex. 
 
Polycystin 
Autosomal dominant polycystic disease (ADPKD) is characterized by renal cysts, 
renal failure and vascular pathology. Disease results in a mutation in one of two genes, 
PKD 1 and 2, which encode polycystin 1 and 2, respectively. Polycystin participates in 
protein-protein (multiprotein membrane-spanning complex) and protein-carbohydrate 
interactions in the extracellular matrix. As early as 1971, Jankowicz et al. reported an 
increase in incidence of berry aneurysms in patients with ADPKD. While mutations in 
both genes have been linked to intracranial aneurysms, work on PKD 1 has revealed a 
specific mutation in chromosome 16p13.3 exon 15 of PKD 1 in two patients. (76). 




developing an aneurysm. Rosetti et al. demonstrated that mutations in the 5’ half of the 
gene was associated with poorer prognosis (77). The prevalence of asymptomatic 
intracranial aneurysms in patients with ADPKD is five times that of the general 
population (54, 78). The average age of aneurysmal rupture is 41, a decade earlier than 
sporadic cases (78-80). One could speculate that the PKD 1 gene either encodes multiple 
proteins or that a mutation in the 5’ end produce a dominant negative. The relationship 
with PKD1 and intracranial aneurysms is rather complex and possibly due to one of the 
multiple proteins encoded by the PKD1 gene. 
 
Fibrillin 
Marfan syndrome, an autosomal dominant disorder of the connective tissue, 
affects the cardiovascular, skeletal and ocular system. It is characterized by 
arachnodactyly, unusual height, pectus abnormalities, enlargement of the aorta and 
possibly aortic aneurysms. The disease is due to a mutation in the gene encoding fibrillin 
(FBN1) located on chromosome 15q21.1. There is debate over the association between 
FBN1 mutation and intracranial aneurysms. A recent study of 25 autopsy cases with 
Marfan syndrome revealed no statistical difference in the prevalence of intracranial 
aneurysm in patients with and without Marfan syndrome. 
There has been no association between FBN 1 mutations and IA, however that is 
not the case for thoracic aortic aneurysms (TAA). Two influential studies have linked 
chromosomes 5q13-q14 and 11q23.2-q24 with aortic and thoracic aneurysms (81, 82). 
The pathogenesis of aortic and thoracic aneurysms is likely similar to that of intracranial 
aneurysms and identification of the gene and gene products of one may divulge a wealth 




families with both intracranial and thoracic aortic aneurysms in an effort to identify 
common gene mutations. 
 
Genome-Wide Linkage Analysis 
The discrepancy in results from the above-mentioned studies reveals the 
limitations of candidate gene analyses.  While approaches driven by hypotheses regarding 
disease mechanisms are intuitively attractive, experience has shown repeatedly that 
positional cloning is the most productive method for isolating causative genes when the 
pathophysiology and molecular biology of a disorder is not well elaborated.  For 
example, in other complex disorders such as hypertension, positional cloning approaches 
by our laboratory revealed 19 genes that contribute to human blood pressure homeostasis, 
some defining novel physiological pathways that would have been extremely difficult to 
predict prior to our studies being completed (83).  Importantly, the results of these types 
of analyses serve as the basis for a wide array of hypothesis driven investigations that can 
elaborate the mechanisms by which a particular gene or genes, once identified, contribute 
to a disorder of interest. 
 To date, a number of studies have used linkage approaches to attempt to 
identify loci contributing to IA risk (57, 58, 72, 74, 75, 84-86).  Sib-pair studies in the 
Japanese and Finnish populations and a recent report of a consanguineous Dutch family 
have identified additional candidate intervals (58, 85, 87).  However, only two intervals 
have significant genome-wide linkage and have not been disproven; 19q13.3 in the 






Genetics of Complex Disease 
 Although many diseases have genetic components, relatively few segregate in 
Mendelian fashion with an identifiable single gene. A number of explanations may 
account for this observation. First, the disease may be attributable to inheritance of a 
single gene of incomplete penetrance, in which case only a fraction of recipients of the 
mutant gene may develop the disease.  Second, the disease may be caused by the 
combined effects of multiple factors in individual subjects- these factors may be a 
combination of genetic and environmental exposures, obscuring the effects of inheritance 
of each susceptibility gene.  Until recently, it seemed that the identification of genes for 
these multi-factorial traits was an insurmountable barrier.  However, the ongoing 
revolution in genetic analysis now permits us to identify genes for complex disorders 
such as IA in which there is a likely genetic component in some patients. 
Importantly, the advent of imaging studies have revealed that IA is much more 
common in the general population than had been previously recognized, with estimates of 
the population prevalence ranging up to 10% (11).  With a high prevalence such as this, it 
becomes increasingly likely that, as a general rule, this trait will prove to be of multi-
factorial determination rather than due to inherited variation in a single gene.  The upside 
to this observation, however, is that it is highly likely that one will be able to identify a 
sizable cohort of multiplex families relatively rapidly by ascertaining multiplex families 
through affected index cases.  Moreover, the availability of large pedigrees still provides 
the opportunity to identify the unusual circumstance in which IA is transmitted as a 
consequence of a mutation in a single with major effect. Consistent with these 
observations, since 1994 we have collected nearly 142 families including both large and 




Large kindreds with high incidence and prevalence of IA are likely due to a single 
gene responsible for the large effect.  Therefore, genome-wide linkage analysis of these 
kindreds will allow one to find the chromosomal position of the disease gene by using 
genetic markers. Confining analysis to a single or a few large families minimizes the 
chance of obscuring linkage due to genetic heterogeneity in which the disease is caused 
by mutation in different genes in different families. The disadvantage is that it is unclear 
whether genes identified in such families will prove to play a role in the general 
population or whether they will be of significance only in rare families.  Further 
complicating things, the ability to collect large extended kindreds may prove to be 
exceptionally difficult due to the lethality of the trait, such that samples from known 
affected subjects are unavailable.  Such analysis is confounded by the uncertain genotype 
of unaffected subjects.  
We plan to use the large extended families we have already collected to identify a 
single gene of major effect using parametric linkage analysis.  Once a locus is identified, 
we propose to confirm the loci by analyzing additional families.   
 
SPECIFIC AIMS 
 The goal of my thesis was to identify the genetic and environmental causes of IA. 
The primary project was to discover the genetic causes of intracranial aneurysms by 
studying the largest-yet-reported kindred with IA. The other large IA families in our 
database were used to help confirm and develop a more thorough understanding of the 
molecular genetics of IA.   
The second stage of the project was to define the environmental risk factors 




risk factors associated with the rupture of aneurysms ≤ 7 mm in size in a consecutive 
series of patients. We hope to identify patient-specific risk factors that should be 
considered along with IA size in determining rupture risk and treatment decisions. 
 
MATERIAL AND METHODS 
Patient Recruitment 
 Through collaborations with vascular neurosurgeons at a number of domestic and 
international centers, we have established the Yale Brain Aneurysm Database (table 1). 
Study investigators from Yale and / or physicians caring for the patient discussed 
participation in the study with the index patient.  Similarly, relatives were contacted and 
recruited to the study either by the Yale group or the physician of the index case (after 
appropriate HIC / HIPAA consent has been obtained). 
 Both patients with sporadic (< 2 affected members within kindred) and familial 
disease (> 2 affected members within kindred) were enrolled in this database. Since 1994, 
we have screened over 3000 patients with IA and identified 142 multiplex families with a 
total of 345 affected patients.  Twenty-one of these families have more than 4 affected 
members and 4 of them have more than 7 affected members. These families are large 
enough to support linkage independently.  A representation of a number of the large 
families is shown in Figure 1.  While some families fit an autosomal pattern, analysis of 
IA pedigrees show that inheritance of IA is complex. We believe these patients and 







Table 1:  List of Collaborators and their respective institutions 
 
 
Medical Center Collaborator 
Beth Israel Medical Center Alejandro Bernstein M.D. 
Columbia University Sander Connolly M.D. 
Harvard - Brigham and Women's Hospital Robert Friedlander M.D. 
Harvard - Brigham and Women's Hospital Dong Kim M.D. 
Harvard – Massachusetts General Hospital Christopher Ogilvy M.D. 
Memorial University,  Newfoundland Canada Falah Maroun M.D. 
Northwestern University Hunt Batjer M.D. 
Northwestern University Issam Awad M.D. 
St. Louis University Saleem Abdulrauf M.D. 
Stanford University Gary Steinberg M.D. 
Istanbul University, Turkey  Necemettin Pamir M.D. 
Istanbul University, Turkey Mehmet Kaynar M.D. 
University of Pittsburgh Daniel Wecht M.D. 
Yale University Arun Amar M.D. 
 
Patient Questionnaire 
 The first approach to identification of multiplex families was via questionnaire 
administered to IA patients (see appendix). This approach was simple, rapid, and selected 
for more severely affected subjects by virtue of the severity of disease presenting to 
medical attention.  This questionnaire includes questions regarding the patient’s current 
health, past medical and surgical history, medications, allergies, and family history of IA, 
stroke, and cerebral hemorrhage. In addition, participants were specifically asked about 
histories of known causes of aneurysm or cerebral hemorrhage, i.e., diagnoses such as 
Ehlers-Danlos, Polycystic Kidney Disease, and GRA.  Data regarding the patient’s 
history was obtained either directly from the patient or through participating physicians.     
 The questionnaire was completed either with supervision from study personnel or 
by direct mailing to study participants for completion at home. Follow-up phone calls 
helped ensure complete data capture.  Previous protocols reveal a greater than 90% 
response rate, and our protocol had similar response rates. Patients were often aware of 




Relatives identified with history of aneurysm or SAH were directly contacted by study 
personnel to obtain medical records to either confirm or exclude the diagnosis.  
 Once relatives are identified, we expanded the pedigree to include all distant 
relatives in order to identify the total number of living affected members and determine 
at-risk siblings and children.  Individuals with unknown phenotype were imaged using 
MRA or CTA.  Finding a family with high prevalence of disease increased the likelihood 
that a single gene accounts for most or all of the risk of aneurysm development. 
 
Phenotype Assignment 
  Phenotype was ascertained through MRI/A, CTA or cerebral angiography. 
Families with at least one additional affected individual (total of two affected) were 
selected for study.  Medical records of relatives helped determine affection status. Those 
with unknown phenotype were screened by using non-invasive tests such as MRA or 
CTA (which was indicated clinically).  In cases where the diagnostic imaging studies 
were performed at outside institutions, we obtained official radiological reports of 
diagnostic studies. Relatives were classified as affected if presence of IA during these 
imaging techniques.  Unaffected relatives <30 years old were classified as phenotype 
unknown.  All phenotypes were assigned prospectively by Dr. Gunel.  
 Screening of family members with more than 2 affected is indicated clinically 
(89-93) and has been funded by insurance companies.  Despite the consensus within the 
neurosurgical community regarding scanning of these at-risk individuals, funding of the 
imaging tests is often a potential problem with the insurance companies.  In a number of 
occasions when we encountered this problem, one-to-one discussion with the insurance 







Representation of several of the large kindreds with intracranial aneurysms in the Yale Brain Aneurysm 
Database. Affected and unaffected individuals are shown as blackened and nonblackened symbols, 




Record Review  
In order to identify eligible patients with SAH, we initially conducted a 
retrospective chart review on 336 patients presenting with any type of intracranial bleed 
from January 2001 to 2004 to the Yale Brain Aneurysm and AVM Center.  Of the 336 
charts reviewed, 100 eligible patients with SAH due to IA ≤ 7mm were identified. 
Subjects with SAH due to aneurysms > 7mm (n = 52) were excluded from the study, as 
were SAH without documented IA on angiogram (n = 26), intracerebral hemorrhage (n = 
97), subdural hemorrhage (n = 40), or bleeding due to trauma (n = 21).  This was the only 
SAH for any of the patients in the ruptured group.  Furthermore, no pre-hemorrhage data 
was available for many of the ruptured patients and this was excluded from the data 
series.  Control subjects were referred due to a variety of reasons ranging from trauma, 
family history, or workup for headaches.  Patients with unruptured aneurysms, but a prior 
history of subarachnoid hemorrhage were excluded from the control group. 
Aneurysm size was obtained from conventional angiography or 3D computerized 
angiography (CTA).  Clinical data, past medical history, and other data were obtained 
from clinic, hospital charts, and radiological reports.  We contacted patients directly in 
the event of incomplete medical record data. In two cases of deceased patients, we 
obtained information from the patient’s next of kin and confirmed these results with the 
patient’s primary care physician.  All aneurysms were berry aneurysms of the circle of 
Willis vessels.  Dissecting aneurysms were excluded from the analysis. 
 
Clinical Definitions 
Patients were coded with hypertension or hypercholesterolemia if either diagnosis 




hypercholesterolemia were identified by the patients’ primary care physicians prior to 
hospital admission or presentation to clinic.  Information regarding smoking, alcohol and 
cocaine use, and family history (intracranial aneurysms hypertension, and abdominal 
aortic aneurysms) was obtained from charts. Age at presentation was defined as the 
patient’s age upon admission, clinic visit, or diagnosis of unruptured aneurysm. 
Aneurysm location was classified as anterior circulation (anterior cerebral, 
anterior communicating, internal carotid, middle cerebral, ophthalmic, para-ophthalmic, 
and posterior communicating artery) or posterior circulation (basilar, posterior inferior 
cerebellar, and posterior / superior cerebellar artery) according to anatomical convention. 
 
Statistical Methods 
Using the Fisher exact test for categorical variables and Spearman’s correlation 
coefficient for ordinal variables, we performed univariate comparisons between putative 
predictor variables and the outcome of aneurysmal rupture.  Age was analyzed as an 
ordinal and dichotomous variable comparing patients younger than 50 years of age to 
those older than 50.  A two-tailed p value < 0.05 was chosen as the threshold for 
statistical significance.  All variables with a p value of 0.2 or lower were entered into a 
multivariable logistic regression model.  Adjusted odds ratios were reported based on the 
results of logistic regression analysis.  Model fit was assessed by standard methods, 
including residual diagnostics and Hosmer-Lemeshow goodness-of-fit testing.  Model 
performance was assessed by the Nagelkerke R2 estimate and computed prediction errors. 







Under the guidance and expertise of Dr. Tom Morgan, we sought to aggregate all 
previously published data to improve the precision of our estimates in defining the impact 
of risk factors leading to rupture of IA ≤ 7 mm. To accomplish this, we used methods 
previously described for meta-analysis of case-control data  (94) We performed a 
comprehensive literature review by searching PubMed and Medline using various 
combinations of the following keywords: "subarachnoid hemorrhage", "intracranial 
aneurysms", "unruptured", "ruptured", and "risk factors".  In addition, we manually 
searched the bibliographies of existing reports to identify citations not included in 
Medline.  Using previously established guidelines we systematically reviewed these 
articles (95) Our inclusion criteria were: prospective or retrospective study; must contain 
comparison of ruptured vs. unruptured ICA; risk factor data must be reported by 
subcategory of aneurysm size (up to 10 mm accepted as cut-off for subgroup analysis); 
and populations must be comparable in terms of age and co-morbidity.   
 
Preparation of Human Genomic DNA  
 A 20 ml sample of venous blood was collected in acid citrate-dextrose tubes from 
each adult subject and shipped to Yale at room temperature via overnight courier.  For 
pediatric subjects, no more than 10 ml/30 kg of body weight was collected.  DNA was 
prepared by isolation of nuclei followed by proteinase K - SDS lysis and subsequent 
phenol and chloroform extractions, after which the DNA was precipitated with ethanol 
and resuspended in 10 mM Tris, pH 8.0, 0.1 mM EDTA.  For samples that had been 
previously frozen, the yield of intact nuclei was very low, and we consequently modified 




K, following which the protocol followed as above.  This approach was inexpensive and 
had a long standing history of producing good yields.  We have used this protocol for 
over 10 years and have had no problems with PCR amplification, restriction 
endonuclease digestion, cloning, or long-term stability of samples.   
 DNA isolation was performed in a dedicated room to prevent potential 
contamination of the laboratory environment with genomic DNA.  Yield averages 
approximately 1 mg DNA, and was less than 200 ug in only 2% of samples.  Because we 
use 50 ng DNA per PCR reaction, we could genotype 400 markers with only 20 ug DNA, 
leaving large quantities of each sample for subsequent analysis as needed.  The optical 
density at A260 and A280 is read to determine the concentration of each sample, and is 
>1.8 in 98% of samples prepared from fresh blood and 85% of samples prepared from 
frozen specimens.  Primary isolates were stored in eppendorf tubes at –70oC.  Access to 
these samples was restricted to the DNA database manager.  When samples were used, a 
master stock of samples were aliquoted at a concentration of 100 ug/ml in 96-well plates 
and working stock dilutions were prepared from this master stock, and these stocks were 
maintained by individual investigators. 
 
SNP Genotyping   
GeneChip genotyping was performed by and in collaboration with the Keck 
Affymetrix GeneChip Center under the expertise of Shrikant Mane Ph.D. We used a two-
stage design in linkage analysis (96).   We first genotyped all available affected 
individuals (n=6) using an early access version of the Affymetrix 10K GeneChips 
containing 10,044 SNP markers (Affymetrix: Santa Clara, CA) .  The median intermarker 




0.39. The SNPs genotyped on these chips provide an estimated information content 
equivalent to a microsatellite screen density of one marker per 1 - 2.5 cM (97). SNP 
genotypes are obtained by following the Affymetrix protocol for the GeneChip Mapping 
10K Xba Array. Briefly, 250 ng of genomic DNA was digested per sample with the 
restriction endonuclease XbaI for 2.5 h. Digested DNA was mixed with Xba adapters and 
ligated using T4 DNA ligase for 2.5 h.  Ligated DNA was added to four separate PCRs, 
cycled, pooled, and purified to remove unincorporated ddNTPs.  The purified PCR 
products are then fragmented and labeled with biotin-ddATP.  Biotin-labeled DNA 
fragments are hybridized to the mapping 10K array 130 chips for 18 h in a standard 
Affymetrix 640 hybridization oven. After hybridization, arrays were washed, stained, and 
scanned using an Affymetrix Fluidics Station F400 with images obtained by use of the 
Affymetrix GeneArray scanner 2500. Affymetrix MicroArray Suite 5.0 software was 
used to obtain raw microarray feature intensities (raw allele scores (98)). Using 
Affymetrix Genotyping Tools software package we derived the SNP genotypes. 
 
Genechip Data Analysis 
 Using the Genome Analysis Programs provided by Affymetrix, we analyzed 
Genechip data.  We created a UNIX based program (Chunky) that parses the data sheet 
into individual files per chromosome in linkage format by generating a data sheet with 
the following information: chromosome number, SNP markers, Decode Map Distances, 
Genotype Calls, and Allele Frequencies (provided by NetAffymetrix).  
We used multipoint linkage analysis assuming autosomal dominant inheritance 
and assign either a 70, 90, or 99% penetrance. Analysis will be done using the Allegro 




obtained from Affymetrix (http://www.laboratorytalk.com/news/aff/aff101.html). 
However, since a number of our pedigrees had a mixture of different ethnic groups, the 
allele frequencies provided by Affymetrix which was based on 54 individuals, may not 
have been suitable for the study population. Therefore, we also examined the robustness 
of linkage analysis using alternative approaches to specifying allele frequencies. 
The 10K Genechips provided enough power to identify broad structures in the 
sample using statistical methods (e.g. the STRUCTURE program developed by Dr. 
Pritchard and colleagues).  In this analysis, unrelated individuals from each family were 
used to infer population structure.  This allowed us to group families into more 
homogeneous groups.  Then based on the inferred groups, we considered three 
approaches for allele frequency specification.  First, for groups with a large number of 
families, we collected data to infer allele frequencies based on unrelated individuals in 
these families.  Second, as these large groups likely corresponded to populations with 
known allele frequencies, e.g. European Americans, and allele frequencies from such 
populations may be available in the public domain (e.g. Affymetrix and the international 
HapMap project), we used population data to investigate the robustness of linkage 
analysis results.  These different approaches ensured that our report of linkage had 
enough confidence that they were not due to allele frequency misspecifications. The map 
order and distances between SNP markers are based on the latest build of the UCSC 
Genome Browser (May 2004, genome.ucsc.edu). 
We confirmed the results of the Allegro program by using GENEHUNTER.  
Since GENEHUNTER can only handle 50 markers at most, we created a Unix based perl 




generates pedigree and data file to be fed into the GENEHUNTER program.  Previous 
runs have shown consistent results between Allegro and GENEHUNTER programs. 
Establishment of proper threshold for statistical significance is crucial for linkage 
association studies.  In general, LOD scores of 3.3 are accepted as significant for 
parametric linkage studies, while for non-parametric tests threshold values p = 2-5×10-5 
or LOD >3.7 are necessary to declare significance (99, 100). Loci were also examined 
under models of locus heterogeneity, using 3.3 as threshold for significance (101).  For 
Mendelian traits segregating in many independent families, if linkage under models of 
locus homogeneity were not apparent after exhausting potentially linked intervals, we 
then performed analysis allowing for locus heterogeneity (101).  If a locus was identified, 
multilocus analysis was performed to search for additional loci that explained disease in 
remaining kindreds (102, 103).  We used the suggested threshold point-wise p-value of 
0.01 which corresponded approximately to a LOD score of 1.5 (99). These guidelines are 
generally accepted for genome-wide significance levels for linkage studies. (99, 100). 
 
Confirmation of Linkage Using Microsatellite Short Tandem Repeat (STR) Markers:   
The above-mentioned approach provides suggestive genomic regions with lod 
scores close to the theoretical maximum lod score. Microsatellite short tandem repeat 
(STR) markers were identified within these regions using the physical map data from the 
UCSC Genome Browser (May 2004, genome.ucsc.edu). These were genotyped for 
further mapping using all available members of a particular family, affected and 
unaffected.  This strategy has been often referred as a two-stage design in linkage 
analysis (104). The theoretical properties of this strategy have been explored by 




DESPAIR in SAGE).  We followed these established principles in the selection of 
promising regions to follow up using microsatellite markers. All genotyping for 
microsatellite analysis were performed by polymerase chain reaction, with detection of 
fluorescent products on an ABI 3700 sequencer from Applied Biosystems equipped with 
Genescan and Genotyper software (ABI, Norwalk, CT).   
PCR reactions were performed in 96-well plates using MJ Research DNA Engine 
Tetrad thermal cyclers, using 50 ng DNA as template in a 10 uL reaction (MJ Research: 
Waltham, MA).  The reaction mixture contains 1 uL 10X buffer, 1.25 nmole of each 
dNTP, 50 pmole of each primer.  PCR conditions involve denaturing for 30 sec at 95oC, 
annealing at specified temperature for 30 sec, elongation for 45 sec at 72oC, for 35 cycles.  
 
Electrophoresis 
 Genotyping and electrophoresis were performed in collaboration with the Keck 
Laboratory at Yale.  Keck DNA Sequencing Resource provided high volume DNA 96- or 
384-well plate genotyping under its DNA Sequencing Resource.  During 2002, the DNA 
Sequencing Resource completed 164,910 services for 286 Yale and 102 non-Yale 
investigators at 52 different institutions.  Detailed information regarding this service is 
available at: http://info.med.yale.edu/wmkeck/dnaseq.  Sequence turnaround time is 
typically two to three days for all services offered.   
Advantages of the ABI 3700 include automated sample loading, shortened run 
times, and elimination of gel pouring and lane tracking.  One uL of pooled sample were 
mixed with 2.0 uL formamide, 1 uL ROX labeled size standard and 1 uL of loading 




PCR mixtures were loaded on the sequencer which automatically transfers and injects 
individual samples into 96 glass capillaries filled with a stationary polymer.  
After electrophoresis through the capillary tubes, the samples were ejected into a 
transparent cuvette, which were scanned by a laser beam that detects fluorescence.  The 
ABI 3700 capillary sequencer cannot distinguish between TET and 6-FAM labeled PCR 
products.  To avert this problem, a novel dye, NED, has been developed by Perkin-Elmer 
to replace TET in ABI 3700 runs.  We converted the TET labeled primers (N=139) used 
for the ABI 377 to the NED label.  In addition, ROX-labeled size standards were used 
instead of TAMRA labels. Genotypes are obtained with the ABI 3700 (Perkin Elmer, 
CA) DNA sequencers using the compatible Genescan and Genotyper software programs.   
Once the data was read, it was processed and stored as a sample file in the 
instrument database and displayed as an electropherogram.  The sample files were 
imported into the Genescan analysis software (Version 3.5 NT) and run on a PC 
compatible computer with the Windows NT operating system.  Sample sizes were 
calibrated using the Genescan 500 ROX standard.  After analysis with the size standard, 
the samples files were imported into the Genotyper software (Version 3.5) for 
determination of genotypes.  Allele sizes were determined by an investigator blinded to 
patient characteristics.  The allele size data were exported into a data sheet and converted 
to allele numbers and associated with patient identification numbers and phenotypic 
status for analysis of linkage.   
 
Data Management and Storage 
All GeneChip data was stored in Sun Sparc workstations and all microsatellite 




CD-ROM and UNIX-based linkage input and output were backed up on high capacity 
tape drives.  ABI files containing sequence runs which were typically 25-28 MB in size 




SAH secondary to IA ≤ 7 mm occurred in 76.5% of patients with pre-existing 
hypertension, whereas only 55.9% of people with normal blood pressure experienced IA 
rupture. In the univariate analysis, hypertension was a significant risk factor for IA ≤ 7 
mm rupture with odds for rupture of 2.58 (p value = 0.01). 
  
Aneurysm Location  
Although the majority of aneurysms were in the anterior circulation, rupture rates 
differed greatly according to aneurysm location. Within the unruptured group, carotid 
(n=15), MCA (n = 13) and ACoA (n = 8) IAs were the most common. Among the SAH 
group, ACoA (n = 26), PCoA (n = 26), and MCA (n = 19) were the most common 
locations of IAs. Eighteen of the 21 (85.7%) aneurysms located in the posterior 
circulation ruptured, whereas 82 of the 130 (63.1%) anterior circulation IAs ruptured.  
Posterior circulation conferred increased risk for IA rupture, OR = 3.51 (p < 0.05). 
 
Age of Presentation 
The median age of patients in our sample was 52. We chose to dichotomize at 50 
years old as this is a clinically useful cutoff point where surgical morbidity and mortality 




significant correlation between age and rupture in the univariate analysis (Spearman’s rho 
= -0.11; p = 0.17). However, the adjusted multivariate analysis showed a risk increase of 
2.6% (p = 0.07) with each one-year decrease in age. 
 











Age < 50 years 49/69 (71.0) 1.49 (0.71, 3.13) 0.30 
 ≥ 50 years 51/82 (62.2)  
 
 
Sex Female  81/123 (65.9) 0.91 (0.35, 2.37) 1.00 
 Male  19/28 (67.9)  
 
 
IA size 5-7 mm  50/73 (68.5) 1.22 (0.59, 2.53)  0.61 
 1-4 mm 50/78 (64.1)  
 
 
IA number 2+ 23/37 (62.2) 0.79 (0.34, 1.83) 0.55 
 1 77/114 (67.5)  
 
 
IA location Posterior  18/21 (85.7) 3.51 (0.95, 19.4) 0.05 
 Anterior 82/130 (63.1)  
 
 
Hypertension* Yes 62/81 (76.5) 2.58 (1.21, 5.53) 0.01 
 No 38/68 (55.9)  
 
 
Hypercholesterolemia* Yes 27/40 (67.5) 0.74 (0.30, 1.86) 0.52 
 No 56/76 (73.7)  
 
 
Smoking* Yes 59/83 (71.1) 1.26 (0.56, 2.83) 0.57 
 No 35/53 (66.0)  
 
 
Cocaine use* Yes 5/7 (71.4) 1.08 (0.16,12.3) 1.00 
 No 44/63 (69.8)  
 
 
Family history IA* No  77/111 (69.4) 1.51 (0.60, 3.75) 0.38 
 Yes 18/30 (60.0)  
 
 
Family history HTN* Yes 23/31 (74.2) 1.52 (0.58, 4.10) 0.40 
 No 72/110 (65.5)  
 
 
Family history AAA* Yes 3/3 (100) Undefined 0.55 
 No 92/138 (66.7)   





Of the 336 patients with intracranial hemorrhage in this study, 152 had SAH due 
to an aneurysm; 100 (65.7 %) of these were found to have an aneurysm < 7 mm in size.  
As shown in Table 2, aneurysm size ranged from 1 to 7 mm. The median size in the 
rupture group was 5 mm; 74 patients had aneurysms of 5 mm and greater, while 78 
patients had aneurysms between 1 and 5 mm. Size was not an independent risk factor for 
IA rupture under 7 mm (unadjusted OR = 1.22; p value = 0.61).  The correlation between 
aneurysm size and rupture was not statistically significant (Spearman’s rho = 0.10; p = 
0.22).  Figure 2 presents the respective distributions of ruptured and unruptured 
aneurysms by size in millimeters, showing no impact of size on risk of rupture.    
 
Figure 2: 
Frequency of subarachnoid hemorrhage (SAH) in patients with intracranial aneurysms (IA) by IA size. 















Sex, Hypercholesterolemia, Smoking, and Cocaine Use  
Similar to previous studies, more females (n = 123) than males (n = 28) presented 
with IA. However, there was no statistically significant relationship between sex and risk 
of rupture (p = 1.00). Additionally, neither hypercholesterolemia (p = 0.52) nor smoking 
(p = 0.57) were associated with rupture. Cocaine use was also not statistically significant 
(p = 1.00), although lack of data in many charts limits the interpretation of this finding. 
 
Logistic Regression Analysis 
There was a statistically significant association between hypertension and the risk 
of IA rupture (p = 0.01).  In addition, there was an increased risk of IA rupture with 
posterior location (p = 0.048).  There was an insignificant inverse correlation between 
age and risk of rupture (Spearman’s rho = -0.11; p = 0.17).  No other variable was 
associated with IA rupture at the p ≤ 0.2 level.  Thus, we entered age, hypertension, and 
aneurysm location into a logistic regression model.  Inclusion of these three variables 
explained 14% of the variance in outcome (Nagelkerke R2 = 0.14).  The multivariable 
model performed better for predicting rupture (89% correct) than non-rupture (24.5% 
correct).  Overall, the model's predictive accuracy was 67.8%.  
Hypertension was an independent risk factor for IA rupture, with an adjusted odds 
ratio (95% CI) of 3.05 (1.33, 6.25), and p value = 0.004.  Likewise, posterior aneurysmal 
location conferred increased risk for IA rupture, OR = 5.35 (1.15, 25.0), p = 0.03.  With 
each one-year decrease in age, the risk of IA rupture in this sample increased by 2.6% 
(OR = 1.03, 95% CI 1.00, 1.07; p value 0.07).  
 
Meta- Analysis and Literature Review 
A thorough review of literature identified 25 studies that reported risk factors for 




our own data (Table 3).  The identified studies were excluded due to violation of one of 
two criteria; (1) study did not contain comparison of rupture vs. non-rupture of IA; or (2) 
study did not report risk factor data by subcategory of aneurysm size (up to 10 mm 
accepted as cut-off for subgroup analysis) in both cases and controls. 
 
Table 3:  Literature review results of 25 studies comparing SAH and risk factors 
 
Author Citation Type of Study Exclusion criteria* 
 
De La Monte et al. 
 





Asari et al. Clin Neurol Neurosurg 95, 205-14 (1993) Prospective 2 
Juvela et al. Stroke 24, 639-46 (1993) Prospective 2 
Ujiee et al. Stroke 24, 1850-6 (1993) Retrospective 2 
Rosenorn et al. Br J Neurosurg 8, 73-8 (1994) Prospective 1 
Mizoi et al. Surg Neurol 44, 114-20 Prospective 2 
Taylor et al. J Neurosurg 83, 812-9 (1995) Prospective 2 
Qureshi et al. Neurosugery 43, 22-6 Retrospective 1 
Menghini et al. Neurology 51, 405-11 Prospective / Retrospective 2 
Juvela et al. J Neurosurg 92, 390-400 (2000) Prospective 1 
Juvela et al. Stroke 31, 392-7 (2000) Prospective 1 
Juvela et al. J Neurosurg 93, 379-87 (2000) Prospective 2 
Nanda et al. Neurosurgery 46, 1063-7  Retrospective 1 
Qureshi et al. Neurosurgery 46, 44-50 (2000) Prospective 1 
Roos et al. Neurology 54, 2334-6 (2000) Prospective 1 
Ellamushi et al. J Neurosurg 94, 728-32 (2001) Retrospective 1 
Forget et al. Neurosurgery 49, 1322-5 Retrospective 1 
Isaksen et al. J Neurol Neurosurg Psych 73, 185-7 (2002) Retrospective 1 
Weir et al. J Neurosurg 96, 64-70 (2002) Retrospective 2 
Winn et al. J Neurosurg 96, 43-9 (2002) Retrospective 1 
Juvela et al. Stroke 34, 1852-7 (2003) Prospective 2 
Matsumoto et al. Surg Neurol 60, 516-22 Prospective 1 
Ogilvy et al. Neurosurgery 52, 82-7 Prospective 1 
Wiebers et al. Lancet 362, 103-10 (2003) Prospective / Retrospective 2 
Ohashi et al. Surg Neurol 61, 239-45 (2004) Retrospective 1 
 
Exclusion criteria:  (1)  Study did not compare rupture vs. no rupture of IA   







IA 20 kindred. Affected and unaffected individuals are shown as filled and unfilled symbols, respectively. 
Individuals I-2, II-5, and IV-1 were assigned affection status unknown prior to linkage analysis and as such 
are depicted with grey symbols. The genotypes of STR marker loci spanning 14 cM at 1p35-36 are shown 
and segments of the haplotype linked to the disease phenotype are enclosed in a box.  
 
IA 20 Phenotype 
We focused our efforts on the IA 20 family (fig. 3), because it has the largest 
number of affecteds within our database and is also has the largest number of affecteds 
within a family reported in the literature (42).  When first described, the IA family had 
six members with proven IA, all in generation II.  The pedigree has since been extended 
and further characterized.  In total, there are now 10 documented IAs, one subject with 
distinctive multiple intracranial vessel occlusions and extensive collateral vessel 
formation of unknown etiology (subject III-3), and one subject with abdominal aortic 
aneurysm (AAA) at a young age (age 32; individual II-5); this latter trait is sometimes 




the patient with multiple intracranial vascular occlusions were classified as affected and 
the one with AAA was prospectively classified as phenotype unknown.   
There are also 12 unaffected descendents of subject I-2. Of these, eight were 
asymptomatic over age 30 and had negative screening MRI or angiography (individuals 
II-3, II-6, II-11, II-14, III-1, III-2, III-8, IV-2); three offspring of unaffected subjects were 
asymptomatic over age 30 and did not have screening studies (individuals III-4, III-9, III-
10); one was asymptomatic under age 30 without screening studies (individual IV-1).  
For linkage studies, this latter subject was classified as phenotype unknown, and the 
others were classified as unaffected.    
 





















* SAH: subarachnoid hemorrhage;  
ACA: anterior cerebral, ACoA: anterior 
communicating, ICA: internal carotid,  
MCA: middle cerebral, OphtA: ophthalmic arteries. 
 
 
Clinical features of affected members are presented in Table 4.  Age of diagnosis 
of IA ranged from 21 to 53 years by MRA or angiography prior to SAH (n = 7), and from 
ages 29 to 57 for patients presenting with SAH (n = 4).  There are scant risk factors for 
IA among kindred members; specifically, there is a history of hypertension in only one 
AFFECTED 
ID Aneurysm Location * 
Age of 
Onset 
II-2 ACoA 38 
II-7 ACA, Lt MCA 53 
II-9 ACoA 40 
II-15 Lt MCA 29 
II-16 Lt MCA (SAH) 32 
II-17 OphtA (SAH) 57 
II-18 Rt MCA, ACoA (SAH) 32 
II-19 Lt ICA (SAH) 29 
III-3 Bilateral MCA occlusion 30 
III-7 Lt MCA 36 
IV-3 Basilar, Rt MCA X 2 21 
UNAFFECTED 
ID Study 
II-3 Normal Angiogram 
II-6 Normal Angiogram 
II-11 Normal Angiogram 
II-14 Normal Angiogram 
III-1 Normal Angiogram, MRA 
III-2 Normal MRI, MRA 
III-4 No study 
III-8 Normal Angiogram 
III-9 No study 




II-5 Normal Cerebral Angiogram-AAA 




individual and while smoking was prevalent among both affected and unaffected family 
members, there was no significant difference between the two groups (8 of 10 affected 
and 10 of 12 unaffected).  Specifically, there is no history of polycystic kidney disease 
(no history of end stage renal disease, and no serum creatnine level > 1.5 mg/dl); no 
history of Marfan syndrome (no history of aortic dissection, ectopia lentis, etc.); no 
history of Ehlers Danlos (no history of hypermobile joints, hyperextensible skin, or easy 
scarring). Finally, in neither the affected only nor the affected plus unaffected genome-
wide linkage analysis (see below) was there evidence of linkage to known loci for any of 
these syndromes. Members of both genders are affected, the trait is present in consecutive 
generations, all affected members are the offspring of either known or suspected IA 
cases, and approximately half the offspring of such subjects have IA (fig. 2).  These 
findings are consistent with autosomal dominant transmission of IA with high penetrance. 
 
Linkage Analysis 
An average of 9468 genotypes was scored per subject (SNP call rate range: 91% – 
97%). To analyze the Genechip data for linkage we created a UNIX based program 
(Chunky) that parses the data sheet into individual files per chromosome in linkage 
format.  Information captured includes chromosome number, SNP markers, map 
distances, genotype calls, and allele frequencies. 
We used multipoint analysis of linkage, we specified the disease locus as 
autosomal dominant, with penetrance that varied from 70% to 99%, a mutant disease-
gene frequency of 0.001, and a phenocopy rate of 0.001. SNP allele-frequency data for 
the white population, as supplied by Affymetrix, were used for the analysis of linkage, 






Analysis of linkage in IA 20 from GeneChip data of affected individuals only. Linkage graphs for all 





Figure 4   continued: 
Analysis of linkage in IA 20 from GeneChip data of affected individuals only. Linkage graphs for all 





three intervals with LOD scores near the theoretical maximum of 1.8 (1p34.3-p36.13, 
1q31-q41, and 2p11-p14), with LOD scores of approximately 0 for nearly all of the 
remainder of the genome (fig. 4).  
The LOD scores were confirmed using the GENEHUNTER program. In an 
additional analysis, we specified the trait locus as X-linked dominant, with otherwise 
similar estimates of the trait locus; no interval on the X chromosome achieved a LOD 
score 1_0.2. Additional genotyping with GeneChip of four unaffected individuals yielded 
only these same three intervals with LOD scores of 1.0. Changing the phenocopy rate had 
small effects on the LOD scores and did not identify additional candidate intervals. 
 
 
Table 5: Maximum lod scores for linkage of STRs and IA with varying penetrances 
 
 Interval   Penetrance   
  70%     90% 99% 
1p35 – 1p36 3.4      3.9 4.2 
1q31 – 1q41 1.3            -0.1 -5.6 
2p11 – 2p14 -0.3    -2.3 -6.6 
 
Maximum lod scores are reported for 1p35 – 1p36, 1q31 – 1q41, and 2p11 – 2p14 using STR markers in all family 
members with varying estimates of penetrance. 
 
 
Using data from the University of California–Santa Cruz (UCSC) Genome 
Browser (May 2004) (UCSC Genome Bioinformatics Web site), we identified and 
genotyped from five to nine highly polymorphic di- and tetranucleotide microsatellite 
markers across each of the three candidate intervals in all available kindred members. 
Genotyping for microsatellite analysis was per- n p 23 formed by PCR, with detection of 
fluorescent products on an ABI 3700 sequencer (Applied Biosystems) equipped with 
GeneScan and Genotyper software (Applied Biosystems). The results were analyzed 




autosomal dominant model of the trait locus used above, with penetrance of 70%–99%). 
Our analysis diminished the evidence of linkage to 1q31-q41 and 2p11-p14 (table 5). In 
contrast, it demonstrated that all affected members inherit the same haplotype at 1p34.3-
p36.13; this haplotype was transmitted to none of the unaffected members (fig. 3). 
Parametric linkage analysis (with 99% penetrance specified) yielded a maximum 
LOD score of 4.2 at 1p34.3-p36.13 (table 5 and fig. 5); changing estimates of marker 
allele frequencies had negligible effects on the LOD score. The likelihood of linkage to 
1p34.3-p36.13 was nearly 1,000-fold more likely than the next-most-likely interval at 
1q31-q41 (table 5). The LOD score peak occurs at UT646; the LOD-1 interval is flanked 
by loci D1S199 and D1S496 (fig. 5), which define a 12.5-cM interval that corresponds to 
a 15-Mb segment (from 19.3 million bp to 34.9 million bp). This is the same interval 
defined by the GeneChip analysis, which indicated a LOD-1 interval flanked by 
rs950922 and rs514262 that corresponded to a 15.4 million–bp interval (from 21.3 
million bp to 36.7 million bp on 1p34.3-p36.13). 
Analysis of critical recombinants supports localization of the IA locus within the 
specified interval. Affected subject II-9 is recombinant at the distal border, and subject 
III-7 is recombinant at the proximal border (fig. 3). Nearly identical borders define the 
linked interval by SNP analysis. Examination of the LOD-1 interval identified 240 genes. 
Among these, a number of genes have been identified as plausible candidate genes, 
including polycystic kidney disease–like 1, brain-specific angiogenesis inhibitor 2, 









Analysis of linkage with microsatelite markers on 1p35-36 localizes the gene causing IA to a 12.5 cM 
region between markers D1S199 and UT5144 with a maximum lod score of 4.2.  Multipoint analysis of 
linkage comparing segregation of IA and marker loci was performed. The location of maker loci used is 




 The pathogenesis of intracranial aneurysms has been associated with genetic and 
environmental factors; however, a definitive mechanism has yet to be worked out. In this 




aneurysms. Through efforts both domestic and internationally, we have amassed one of 
the largest databases of IA patients – a resource which has enabled us to study the 
environmental and genetic factors associated with formation, growth and rupture of IA.  
Previous genome-wide linkage studies have used affected sibling and / or relative 
pairs to identify various loci throughout the human genome that link to IA (58, 84, 85, 
88). However, the results of these studies have been inconsistent, inconclusive, and have 
not identified a gene leading to IA. Candidate gene studies have been equally 
unsuccessful (58, 84, 88, 106).  
Given the substantial locus heterogeneity, the power of affected sibling pair 
studies or affected relative pair studies is severely limited (107). Alternatively, using rare 
Mendelian forms of IA, we focused on individual families to identify genes and pathways 
that play a key role in the pathogenesis of both the rare and common form of IA (108).  
 
Genetics 
In the present study, we have investigated what we believe is the largest-yet-
reported kindred with IA; genome-wide analysis of linkage provides significant evidence 
that the disease in this family is attributable to inheritance of a single locus at 1p34.3-
p36.13. Our analysis diminished evidence for linkage to 1q32.1 and 2p12 (table 5).  In 
contrast, it demonstrated that all affected members inherit the same haplotype at 1p34-36, 
while this haplotype was transmitted to none of the unaffected members (fig.3). 
Parametric linkage analysis specifying 99% penetrance yielded a maximum lod score of 
4.2 at 1p34-36 (table 5 and fig. 3); changing estimates of marker allele frequencies had 
negligible effects on the lod score.  The likelihood of linkage to 1p34-36 was nearly 1000 




The lod score peak occurs at UT646; the lod-1 interval is flanked by loci D1S199 
and D1S496 (fig. 3), defining a 12.5 cM interval which corresponds to a 15 Mb segment 
extending from 19.3 to 34.9 million base pairs.  This is the same interval defined by 
GeneChip analysis which indicated a lod-1 interval flanked by rs950922 and rs514262, 
corresponding to a 15.4 million base pair interval (from 21.3 to 36.7 million base pairs on 
1p34-36).   
Analysis of critical recombinants supports localization of the IA locus within the 
specified interval.  Affected subject II-9 is recombinant at the distal border, and subject 
III-7 is recombinant at the proximal border (fig. 3).  Nearly identical borders define the 
linked interval by SNP analysis.  
Examination of the lod-1 interval identified approximately 240 genes.  Among these, a 
number of genes have been identified as plausible candidate genes including Polycystic 
Kidney Disease Like-1 gene, Brain Specific Angiogenesis Inhibitor 2, Fibronectin type 
III domain containing gene, and Collagen type XVI α1 gene.  
 To our knowledge, the present kindred is the largest yet reported with IA, with 
10 definitively affected subjects and one likely affected subject.  Genome-wide analysis 
of linkage in this kindred demonstrates complete linkage of IA to a 12.5 cM segment of 
chromosome 1, with evidence for linkage that substantially exceeds thresholds for 
significance.  The phenotyping in the kindred was clear-cut; reclassifying the patient with 
multi-vessel occlusions and extensive collateral growth as phenotype unknown would 
reduce the maximum lod score to 3.9.  Moreover, the lod score was substantially 
increased by inclusion of unaffected family members, supporting high penetrance of the 
trait locus. It is also of note that the subject with the early AAA inherited a segment of 




inheritance at this same locus. It would be of interest to obtain abdominal ultrasounds in 
kindred members in order to determine whether this phenotype commonly co-segregates 
with intracranial aneurysms and/or linked haplotypes.  The pattern of segregation and the 
linkage data indicate that this family defines a new Mendelian form of IA that is 
transmitted as an autosomal dominant trait with high penetrance.  Similar to reported 
cases of familial IAs, members of IA 20 presented with SAH or symptomatic findings at 
an earlier age than typically found in sporadic cases (47). 
 These findings represent a first step in identifying a susceptibility gene for 
intracranial aneurysm.  Other than young age, there are no obvious clinical features that 
would separate IA in members of this family from typical cases in the general population.  
It is presently unknown whether the locus implicated in this study might play a role in 
other common forms of IA.  In principle, it is possible that this might be a one-of-a-kind 
family with a rare mutation resulting in a highly penetrant form of IA.  It is also possible 
that other less penetrant mutations in the same gene or pathway play a role in more 
common forms of IA.  To date, a number of studies have used linkage approaches to 
attempt to identify loci contributing to IA risk (57, 58, 72, 74, 75, 84-86).  Sib pair 
studies from Japanese and Finnish populations and a recent report of a consanguineous 
Dutch family have identified candidate intervals (58, 85, 87).  The only intervals from 
such studies that meet genome-wide evidence of significant linkage is 19q13.3 in the 
Finnish population (88) and 2p13 in the Dutch family (87).   
 The identification of the causative gene in IA 20 will shed light on the pathways 
leading to disease.  Whether this locus or pathway will play a role in more common 
forms of disease remains to be determined.  However, once genes leading to IAs are 




formation and rupture.  Finally, these findings may contribute to improved diagnostic and 
therapeutic approaches to this disease. 
 
Environment 
The management of cerebral aneurysms ≤ 7 mm remains a controversial issue in 
neurosurgery.  Numerous studies have outlined guidelines for treating unruptured 
aneurysms that range from > 7 to 10 mm. However, despite the clinical observation that a 
substantial number of IA ≤ 7mm also rupture, relatively little is known about the risk 
factors associated with the rupture of these smaller aneurysms.  In this study, we show for 
the first time that among patients with aneurysms ≤ 7 mm, hypertension, younger age, 
and posterior circulation are significant risk factors for rupture  
We retrospectively analyzed aneurysm characteristics and social history 
demographics of patients with both unruptured and ruptured aneurysms ≤ 7 mm.  In our 
study population, the average size of ruptured and unruptured aneurysms was 4.65 mm 
and 4.33 mm, respectively.  Consistent with published reports, the majority of ruptured 
aneurysms ≤ 7 mm in our study were of the anterior circulation, mainly the anterior 
communicating (ACoA) and middle cerebral arteries (MCA).  In our unruptured 
population, the majority of aneurysms were also of the anterior circulation (carotid and 
middle cerebral arteries).  Interestingly, however, posterior aneurysmal location conferred 
substantially increased risk for IA rupture. Those whose aneurysms ruptured were more 
likely to have poorly controlled hypertension. 
Our findings extend those of previous retrospective reviews of aneurysmal rupture 
risk.  In particular, aneurysms ≤ 7 mm rupture and the majority of these aneurysms are of 




prospective arm of the ISUIA study, showed that aneurysms of the posterior circulation 
were more likely to rupture at smaller sizes (≤ 7 mm) (15)  However, based on a 
comprehensive systematic review of the medical literature, we found no published data 
meeting our liberal inclusion criteria for combination with our own data.  Accordingly, to 
the best of our knowledge, this study is the first to report on risk factors specifically 
associated with the rupture of aneurysms less or equal to 7 mm in diameter.   
A recent study analyzing 280 ruptured aneurysms showed that 74% were smaller 
than 10mm, with a mean size of 7.6 mm (33)  The mean size of ruptured aneurysms in 
patients who were normotensive, had medically controlled hypertension, and had poorly 
controlled hypertension were 8.3, 7.4, and 6.5mm, respectively.  Furthermore, patients 
with a family history of subarachnoid hemorrhage or who had poorly controlled 
hypertension were more likely to have ruptured aneurysms less than 5mm.  With respect 
to location, ruptured aneurysms of the anterior communicating artery were smaller on 
average (6.6 mm) than aneurysms in other locations.  These results confirmed the results 
of a previous single-center retrospective analysis that showed that 50% of ruptured 
aneurysms were 6-10 mm in size and 35% were < 5 mm with the majority of small 
aneurysms being of the anterior communicating artery (19) 
The prospective arm of the ISUIA trial outlines the clearest guidelines indicating 
treatment based on size and location of a small, unruptured aneurysm.  This study stated 
that the greatest benefit might be seen when aneurysms > 7 mm of the posterior 
communicating artery are surgically treated in young patients (<50 years of age) (15)  
The recommendation that aneurysms ≤ 7 mm of the anterior circulation in patients with 
no family history of SAH should be left untreated was reinforced by others (32)  




relatively short-term durations of follow-up.  Patients will be interested to know near-
term rupture risks, but SAH can occur following any time interval, making retrospective 
study data essential for surgical decision-making.  
Because the rupture of small aneurysms is a relatively rare event, it is difficult to 
achieve a sample size that is large enough to detect modest risks for rupture. In this study, 
the absence of a statistically significant relationship between such variables as number of 
aneurysms, smoking, and family history of IA should be interpreted with caution.  Type 
II error (false negative) is a possible explanation, and further studies involving multiple 
centers are warranted for the assembly of large, prospective cohorts with the power to 
provide more precise estimates of the risk associated with these clinically important 
variables. Additionally, as a chart review, we were limited in the direct quantification of 
continuous variables.  Data on pre-hemorrhage aneurysm size was inconsistent and often 
unavailable in our patients presenting with SAH and therefore this data was excluded 
from our analysis.  This is another significant limitation of this study.   
Based on our results, we suggest the need for new guidelines incorporating 
relatively young age, hypertension, and posterior aneurysm location as possible factors 
relevant to surgical management of IA ≤ 7 mm.  These patients are at higher risk for 
rupture, and have lower age-related surgical mortality and morbidity risks.  These results 
are consistent with those presented in the ISUIA prospective study, but add additional 
clinically relevant information regarding the subset of patients with IA ≤ 7 mm.  
Furthermore, more rigorous prospective studies with the specific aim of following 







Although the pathogenesis of intracranial aneurysm remains poorly understood, 
there is significant evidence associating environmental and genetic factors with disease. 
Size has long been considered the main risk factor for rupture; however, we demonstrate 
that hypertension, posterior circulation, and relatively young age should also be 
considered. In addition we identify 1p34.3-36.13 as a chromosomal region related to the 
pathogenesis of IA. Although the literature is rich with linkage studies pointing to regions 
throughout the genome, it appears that more than one locus will be involved in the IA 
pathogenesis.  
In short, it is likely that both locus and allelic heterogeneity along with 
environmental factors play a role in IA pathogenesis complicating efforts at disease gene 
identification. Certainly the identification of new genes important in IA pathogenesis will 
provide insight into the primary determinants of this disease and will result in new 
opportunities for early diagnosis in the preclinical setting. Identification of risk factors 
related to formation and rupture of aneurysms will also assist in the understanding of 
disease, while allowing clinicians the opportunity to modify treatment based upon risk. 
Ultimately, it is anticipated that novel therapeutic strategies will be developed which will 













PATIENT INFORMATION SHEET  
 
Name ______________________ Telephone #  _______________________ 
  
Address  ______________________________________________________ 
 
Date of birth __________ Race __________  Gender ________________ 
 
1. How old were you when your aneurysm / stroke was first diagnosed? ________ 
 
2. How many intracranial aneurysms did / do you have? _____________________ 
 
3. Did your aneurysm rupture and bleed? _________________________________ 
 
4. Did you have surgery to treat the aneurysm?    Yes    /     No 
- If yes, what was the date of surgery:  _____________________________ 
 Name of your neurosurgeon: _______________________________ 
  Hospital where operation was performed: _____________________ 
   
5. Do you have high blood pressure: Yes /  No    When was it diagnosed? _______ 




6. Have you ever smoked?   Yes  /  No  
 - If yes, for how many years _______  How many packs a day? ________ 
 
7. Do you drink alcohol / beer / wine / liquor? Yes / No 
 - If yes, what do you drink?  _____   How many drinks per day? ________ 
 
8. Please list any family members that have had an aneurysm or stroke?  




9. Please list any diseases that run in your family:   
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